EVO | tickerfilter.com

Fundamental analysis

Profitability 0%

Dept financing 0%

Liquidity 0%

Performance 0%

Performance

5 Days

-10.00%

1 Month

-17.74%

3 Months

-5.26%

6 Months

-9.20%

1 Year

-21.94%

2 Year

-28.84%

Key data

Stock price

$3.06

P/E Ratio

N/A

DAY RANGE

$2.97 - $3.10

EPS

N/A

52 WEEK RANGE

$2.84 - $4.80

52 WEEK CHANGE

-$21.34

MARKET CAP

0.000

YIELD

N/A

SHARES OUTSTANDING

0.000

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

08-13-2025

BETA

0.00

PUBLIC FLOAT

N/A

AVERAGE 10 VOLUME

$97,375

AVERAGE 30 VOLUME

$212,820

Company detail

CEO: Werner Lanthaler
Region: US
Website: evotec.com
Employees: 4,200
IPO year: 2008

Issue type:
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Evotec SE operates as drug discovery and development partner for pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as diabetes and complications of diabetes, fibrosis, infectious diseases, CNS diseases, oncology, pain and inflammation, immunology, rare diseases, respiratory diseases, and women's health. It has collaboration agreements with Bayer AG; Lilly; Chinook Therapeutics; Novo Nordisk A/S; Galapagos; Pfizer Inc.; CONBA Pharmaceutical Co., Ltd.

EVO - Evotec SE